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Abstract
 
Residual immunity to the smallpox virus raises key questions about the persistence of long-
term immune memory in the absence of antigen, since vaccination ended in 1980. IFN-
 
 
 
–
producing effector–memory and proliferative memory T cells were compared in 79 vaccinees
13–25 yr after their last immunization and in unvaccinated individuals. Only 20% of the vaccinees
displayed both immediate IFN-
 
 
 
–producing effector–memory responses and proliferative
memory responses at 6 d; 52.5% showed only proliferative responses; and 27.5% had no de-
tectable vaccinia-specific responses at all. Both responses were mediated by CD4 and CD8 T
cells. The vaccinia-specific IFN-
 
 
 
–producing cells were composed mainly of CD4Pos
CD45RANeg CD11aHi CD27Pos and CCR7Neg T cells. Their frequency was low but could
be expanded in vitro within 7 d. Time since first immunization affected their persistence: they
vanished 45 yr after priming, but proliferative responses remained detectable. The number of
recalls did not affect the persistence of residual effector–memory T cells. Programmed revacci-
nation boosted both IFN-
 
 
 
 and proliferative responses within 2 mo of recall, even in vaccinees
with previously undetectable residual effector–memory cells. Such long-term maintenance of
vaccinia-specific immune memory in the absence of smallpox virus modifies our understanding
of the mechanism of persistence of long-term memory to poxviruses and challenges vaccina-
tion strategies.
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Introduction
 
Residual immunity to smallpox virus is a burning question
for public health and future vaccine development. It raises
key questions about factors influencing the persistence of
long-term immune memory in the absence of antigen,
since smallpox was eradicated and vaccination stopped
in 1980 (1). It is the ultimate goal of a vaccine to de-
velop long-lived immunological protection against pathogens
through the development of an abundant pool of memory
cells (2, 3). T cell–mediated immune memory, widely
studied in mouse viral infection models, requires clonal
expansion of effector–memory T cells from naive T cells
followed by the contraction and then stabilization of the
size of the antigen-specific memory T cell population (4,
5). After this stabilization, their number is estimated to be
at least 1,000-fold higher than the number of naive T cells
(6). However, it is still unclear how long this immunity can
last and whether the long-term persistence of memory T
cells is determined at priming or if antigen boosts are
needed to maintain this population. According to mouse
models, initial vaccine priming determines the number of
antigen-specific memory CD8 T cells (7–9). Their persis-
tence depends on periodic reexposure to the nominal anti-
gens (3, 10–14) or to cross-reactive heterologous viruses
(15). In humans, the long-term persistence of immune
memory to vaccines is still poorly understood.
The eradication of smallpox (16, 17) makes it possible to
investigate the factors influencing the persistence of vaccinia-
specific memory T cells in vaccinated individuals in the ab-
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sence of the smallpox and vaccinia viruses 25 yr after mass
vaccination ended. Studies during the smallpox vaccination
era, when both smallpox and vaccinia viruses were still cir-
culating, suggested that protective immunity to smallpox
declines 5–10 yr after vaccinia inoculation and accordingly
set a vaccination schedule at 1, 11, and 21 yr (16, 18). Neu-
tralizing antibody responses are considered to decline within
3–5 yr of vaccination (19), whereas T cell responses medi-
ated by proliferating T cells and CTL precursors are thought
to persist for up to 50 yr after immunization (20). A recent
study (21) reports that 90% of vaccinated individuals still
have vaccinia-specific IFN-
 
 
 
–producing CD4 or CD8 cells.
However, the frequency of these cells is very low in some
vaccinees, close to those in unvaccinated controls. Given
that the nominal antigens (smallpox and vaccinia viruses) no
longer circulate, the frequency of short-term cytokine-pro-
ducing effector–memory responses, which are supposed to
depend on antigen presence, was indeed expected to be
low. These cells, however, may not be representative of the
entire vaccinia-specific memory response, which should in-
clude memory T cells capable of expansion and proliferation
against virus challenge. Murine models show that proliferat-
ing or central memory T cells do indeed differ from the
immediate effector–memory T cells: they display distinct
phenotypes and functions and are more protective (3).
However, the distinction between effector–memory and
central memory demonstrated in humans (22) has never
been explored in an appropriate model of long-term T cell
memory and in the complete absence of nominal antigen.
To explore the persistence, intensity, and quality of T
cell memory to vaccinia in the vaccinated population de-
cades after vaccination ended and to better understand the
mechanisms that make possible this long-term maintenance
of memory T cells to vaccines in humans, we simulta-
neously investigated two aspects of vaccinia-specific T cells
in a population of persons vaccinated long ago: their prolif-
eration capacity and the frequency of those producing
IFN-
 
 
 
. Because monitoring vaccine-specific T cells neces-
sitates a precise definition of memory T cell frequencies,
we defined our threshold relative to frequencies in unvac-
cinated unexposed young individuals. Our results showed
clearly that although proliferative memory responses to
vaccinia persisted in 72% of the population and were not
influenced by age or vaccine recalls, an IFN-
 
 
 
 response
above the threshold of the unvaccinated unexposed con-
trols was detected in only 20% of the subjects and declined
after the age of 45 yr, independently of recalls. Recent re-
vaccination boosted both IFN-
 
 
 
 and proliferative responses
in all revaccinated individuals.
 
Materials and Methods
 
Donors.
 
Fresh PBMCs were obtained from 79 volunteers
vaccinated previously against smallpox (age range, 25–68; vacci-
nation at the age of 1–43 yr) including 17 who were revaccinated
after the first vaccination (age range 32–57), and from 10 unvac-
cinated young healthy donors (age range, 20–25), all with their
written informed consent. The sex ratio was 60% women and
40% men. The people included in this study were volunteers for
the French National Emergency Team against Smallpox.
 
ELISpot Assays.
 
The ELISpot assay was run after careful de-
termination of the optimal antigen doses and reproducibility of the
assays in vaccinated individuals as positive controls and naive un-
vaccinated unexposed donors as negative controls. Briefly, PBMC
were infected for 1 h with the live vaccinia Copenhagen wild-type
strain (obtained from M.P. Kieny, Transgène, Strasbourg, France)
at three infectious doses (1, 2.5, and 5 pfu/cell) and tested in tripli-
cate experiments in an ELISpot assay as described previously (24).
Repeated experiments performed on the same samples gave similar
results (100% concordance for spot-forming cells (SFCs)/million
PBMCs with a median coefficient of variation of 9%) for 18 vac-
cinees and for 9 unvaccinated donors. We then selected 1 pfu/cell
as the optimal dose, as did Frey et al. (26). Cells were washed and
added to 96-well ELISpot plates (Millipore) coated with anti–
human IFN-
 
 
 
 antibody (Diaclone). Negative controls were unin-
fected cells with medium alone. Positive controls were uninfected
PBMCs stimulated with purified PHA (1 
 
 
 
g/ml; GIBCO BRL).
Cells were cultured in triplicate wells at 1 
 
 
 
 10
 
5
 
 PBMCs at 37
 
 
 
C
for 18 h. Spots were detected with an automated microscope (Carl
Zeiss MicroImaging, Inc.) and counted as positive if there were at
least 50 vaccinia-specific SFCs/million PBMCs (after subtracting
the background obtained with unstimulated cells). This threshold
for positivity was established by taking into account: (a) the vari-
ability of the background obtained with cells alone (3 
 
 
 
 5 SFCs/
million PBMCs, range, 0–75); (b) the SFCs range in the 10 naive
unvaccinated individuals used as negative controls: median 1.5
SFCs/million PBMCs (range, 0–40 SFCs/million PBMCs); (c) the
laboratory reproducibility of the assay on a given sample; and (d)
the fluctuation over time of individual vaccinia-specific frequencies
at a month’s interval (tested in five individuals; concordance of
100% and coefficient of variation, 29%). This threshold of 50
SFCs/million PBMCs yielded 100% negative results for the naive
unvaccinated unexposed donors.
In some experiments, freshly isolated PBMCs were depleted of
CD8
 
 
 
 cells with magnetic beads, according to the manufacturer’s
instructions (Dynal). The CD4
 
 
 
 enrichment was verified by flow
cytometric analysis (
 
 
 
90% CD3
 
 
 
CD4
 
 
 
 cells).
 
Proliferation Assays.
 
The T cell proliferation assay was run after
a careful determination of the optimal antigen doses and reproduc-
ibility of the assays in vaccinated individuals as positive controls
and naive unvaccinated unexposed donors as negative controls.
Briefly, triplicate wells containing cells (10
 
5
 
) were cultured in
RPMI medium supplemented with 10% AB human serum for 7 d,
with 0.1 pfu/cell Copenhagen vaccinia strain for 7 d in the 3H-
thymidine assay. A prior comparison of three infectious doses (0.1,
0.25, and 0.5 pfu/cell) had been performed with similar results on
blood from both vaccinated and unvaccinated donors. 3H-thymi-
dine was added during the last 18 h of culture, and cells were har-
vested and counted on a Microbeta-plate 
 
 
 
-counter (Beckman
Coulter). Positive responses were defined by a positive stimulation
index of 3 and a minimum 3H-thymidine incorporation of 3,000
cpm as described (38). In the bromodeoxyuridine (BrdU) assay,
performed with a 1 pfu/cell infectious dose, BrdU was added at
100 ng/ml at the beginning of cultures tested at days 3 and 7. Cells
were washed and analyzed by flow cytometric intracytoplasmic
staining as described in the next paragraph.
 
Flow Cytometry Analyses.
 
Fresh PBMCs were stimulated for
1–7 d with autologous adherent 1 pfu/cell vaccinia-infected mono-
cytes. Membrane staining of stimulated T cells used anti-CD8,
anti-CD4, FITC, or Cy-Chrome–conjugated anti-CD45RA, FITC-
or PE-conjugated CD27, PE-conjugated anti-CCR7 or PE-con- 
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jugated CD11a (Becton Dickinson) monoclonal antibodies. Intra-
cellular IFN-
 
 
 
, IL-2, or BrdU detection used anti-IFN-
 
 
 
 
 
, IL-2–PE
or APC, or anti-BrdU–FITC–conjugated Ab staining (Becton
Dickinson). Briefly, cells were fixed with PFA 4% for 20 min,
washed in PBS-FCS 2-0.1% saponin buffer and incubated for 20
min at 37
 
 
 
C with DNase (2.5 
 
 
 
g/ml) in DNase Buffer (Sigma-
Aldrich). Cells were washed in PBS-FCS 2-0.1% saponin buffer
and incubated with the labeled Abs. Flow cytometric analyses were
performed on a FACScalibur™ with CellQuest™ Pro software
(Becton Dickinson) on 
 
 
 
3,000,000 events.
 
Statistical Analyses.
 
Data handling, analysis, and graphic rep-
resentation used Prism 2.01 (GraphPad Software) with a 
 
 
 
2 test.
Statistical significance was set at P 
 
  
 
0.05.
 
Results
 
Quantification of Residual Effector–Memory and Proliferative
Responses to Vaccinia in Long-Term Vaccinees.
 
We first stud-
ied the residual cell-mediated immune responses to the vac-
cinia virus in 89 healthy volunteers: 79 vaccinees, aged 25–
68 yr, who had received one to five vaccinations from 1943
through 1989, and 10 unvaccinated unexposed individuals,
younger than 25 yr. We stimulated PBMCs in vitro with
the live vaccinia virus to activate all donor cells. We chose
live virus because the limited number of CD8 epitopes de-
fined are restricted to the HLA-A2 type (23). We counted
the number of rapidly mobilized, “immediate” vaccinia-
specific effector–memory T cells during this short-term
PBMC stimulation in an 18-h IFN-
 
 
 
 ELISpot assay (Fig. 1
a). Because cell frequencies were expected to be low, the
specificity and sensitivity of the ELISpot assay were carefully
established first (as described in Materials and Methods).
The median IFN-
 
 
 
–producing cell frequency for the 10
unvaccinated donors was 1 SFCs/million PBMCs above
background (range, 0–40) (Fig. 1 a). Therefore, positive
response to vaccinia was defined as 
 
 
 
50 SFCs/million
PBMCs over background, and this threshold, commonly
used for monitoring T cell responses to new vaccines (24,
25), was used to assess the assay specificity. Only 20% (
 
n
 
 
 
  
 
16)
of the vaccinees showed vaccinia-specific effector–memory
cells above this threshold (median for responders, 98 SFCs/
million PBMCs; range, 53–843). Similarly, we defined pos-
itive proliferative responses (Fig. 1 b) in comparison with
responses in unvaccinated donors. In contrast to the low
percentage of vaccinees with IFN-
 
 
 
–producing cell re-
sponses, vaccinia-specific proliferative responses were de-
tected in vitro after 6 d of virus exposure in the PMBCs of
72.5% of the vaccinees (50 of 69 tested) (Fig. 1 a). The si-
multaneous evaluation of both functions showed that: (a)
when detectable (20% of cases), the rapidly mobilized effec-
tor–memory–type lymphocytes producing IFN-
 
 
 
 were al-
ways associated with a proliferative memory response to
vaccinia; (b) 52.5% of the vaccinees displayed only an ex-
pandable pool of memory T cells (without IFN-
 
 
 
 response);
and (c) 27.5% displayed neither effector–memory or prolif-
erating memory T cell responses as defined above (Fig. 1 b).
Simultaneous analysis of proliferative and IFN-
 
 
 
–producing
cells against vaccinia and smallpox thus showed that rapidly
mobilized effector–memory responses and the expandable
pool of memory T cells had clearly distinct patterns of long-
term maintenance in the absence of antigen.
 
Characterization of Long-Term Memory T Cells Specific for
Vaccinia.
 
To assess the cell populations involved in these
vaccinia-specific responses, we first assayed IFN-
 
 
 
 produc-
tion and proliferation after CD8 cell depletion (Fig. 2, a
and b). Residual vaccinia-specific effector and proliferative
responses were still observed in most vaccinated individu-
als; this suggests that CD4 T cells were the major compo-
nent of these persistent effector–memory T cell responses.
That absolute numbers of vaccinia-specific SFCs in the
Figure 1. Residual T cell–mediated immune responses to vaccinia virus in
smallpox vaccinees. We examined fresh PBMCs from healthy individuals
including 79 long-term vaccinees (VAC) (age, 25–68 yr; median, 39) and
10 unvaccinated unexposed volunteers (UNVAC) (age, 19–24 yr; median,
23). (a) Results from IFN-  ELISpot assays after stimulation with the live
Copenhagen vaccinia strain are represented as the percentage of healthy
responders who are long-term vaccinees (black bars) (median for responders,
98; range, 53–843 SFCs/million PBMCs) and unvaccinated volunteers
(white bar). Results from 3H-thymidine proliferation assays after 7 d
stimulation with the live Copenhagen vaccinia strain are represented as
the percentage of healthy responders who are long-term vaccinees (black
bars) (median proliferation index, 15.5; range, 3–163); unvaccinated vol-
unteers (white bars). (b) Reciprocal distributions of ELISpot and prolifer-
ation assays are represented for long-term vaccinees ( ) and unvaccinated
unexposed individuals ( ). Positive responses were defined after analysis
of responses obtained in unvaccinated control individuals: proliferative
stimulation index  3 and IFN- –producing cells  50 SFCs/million PBMCs
after subtraction of the background (shown by dashed lines). The per-
centage of vaccinees in each quadrant is indicated.
Figure 2. Vaccinia-specific
CD4 and CD8 memory cells.
CD8-depleted PBMCs (grey bars)
compared with total PBMCs
(black bars) were tested by
ELISpot assay (a) and proliferation
assay (b). Results are shown for
two representative individuals. 
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CD4-enriched PBMC fractions did not increase suggests
that IFN-
 
 
 
–producing CD8 cells were also involved.
We next analyzed the nature of the vaccinia-specific
proliferative responses after in vitro cell expansion during
culture with the live virus. At day 3, the BrdU incorpora-
tion assay confirmed for the 10 vaccinees tested that both
CD4 (mean 
 
  
 
SEM; 0.46 
 
 
 
 0.25%) and CD8 (mean 
 
 
 
SEM; 0.51 
 
 
 
 0.37%) vaccinia-specific T cells were ex-
pandable (Fig. 3 a). IL-2–producing CD4 T cells were
also detected in two cases and correlated with the inten-
sity of the vaccinia-specific proliferative responses de-
tected in the proliferation assay (Fig. 3 a). However, IL-2
production was undetectable in most cases (unpublished
data). The vaccinia-specific cell expansion assay at 7 d
showed amplification of both CD8 and CD4 cells produc-
ing IFN-
 
 
 
; these represented 7 and 10% of the T cells, re-
spectively (Fig. 3 b). These results showed that both CD4
and CD8 T cells participate in vaccinia-specific memory
responses, with the relative proportions differing among
individuals. They also indicated that in vitro stimulation
of residual vaccinia-specific CD4 and CD8 T cells in-
creased the frequency of effector–memory cells capable of
producing IFN-
 
 
 
.
Figure 3. Vaccinia-specific CD4 and CD8 amplification leads to an
increase in the frequency of effector–memory cells. (a) Percentage of BrdU 
cells in CD8 and CD4 T cells of five vaccinated individuals and two un-
vaccinated individuals after fresh PBMCs infected with either 1 pfu/cell
vaccinia strain or medium alone were cultured for 3 d in the presence of
BrdU (background subtracted). The number of IL-2–producing cells in
the CD4 population was estimated by flow cytometric analysis at 48 h
after antigenic stimulation (0–80 IL-2–producing cells/million CD4 
cells). (b) Representative flow cytometric analyses show IFN-  produc-
tion in vaccinia-specific T cells expanded for 7 d and restimulated on day
7 by monocytes infected with vaccinia for an additional 18 h at 1 pfu/cell
(unvaccinated and long-term vaccinated individuals).
Figure 4. Phenotypic analyses of vaccinia-specific memory T cells. In-
tracytoplasmic IFN-  production by flow-cytometry assays of CD4 T
cells after 18 h stimulation with vaccinia virus in selected volunteers with
high frequencies of vaccinia-specific cells ( 200 SFC/million PBMCs)
(a–c, left panels top quadrant, unstimulated cells; bottom quadrant, vaccinia-
stimulated cells). (a) CD45RA and CD11a expression gated on total
CD4Pos cells or CD4PosIFN- Pos cells (in two individuals, I5 and I12;
78 and 70% of vaccinia-specific IFN- –producing CD4 cells were
CD45RANegCD11aPos). N, naive T cells; E, effector T cells; M, mem-
ory T cells. Flow cytometry analyses for CCR7 expression showed that
N, CCR7Pos, E, CCR7Neg, and M, CCR7Pos/Neg (not depicted).
(b) CD45RA and CD27 expression are gated on either total CD4Pos
cells or CD4PosIFN- Pos cells. Experiments were performed with five
individuals: I1, I2, I5, I7, and I9 (60–70% of vaccinia-specific CD4 cells
were CD45RANegCD27Pos). (c) CD45RA and CCR7 expression are
gated on either total CD4Pos cells or CD4PosIFN- Pos cells. Experi-
ments were performed with two individuals: I1 and I2 (80–91% of vaccinia-
specific CD4 cells were CD45RANegCCR7Neg). 
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We further investigated the phenotypic characteristics of
the vaccinia-specific T cells to assess in particular the effec-
tor–memory late/early cell surface markers proposed for
humans (3). Using two distinct definitions, we found that
most of the vaccinia-specific IFN-
 
 
 
–producing residual
vaccinia-specific T cells, assessed ex vivo, displayed charac-
teristics of memory CD4 T cells. The vaccinia-specific
IFN-
 
 
 
–producing CD8 cells were below detectable levels.
Specifically, most vaccinia-specific CD4
 
 
 
 cells were CD45
RANegCD11aHi (70–78%) or CD45RANegCD27Pos
(60–70%), whereas a few met the definition of effector T
cells, i.e., CD45RAPosCD11ahi (12–17%) or CD45RAPos
CD27Neg (10–13%) (Fig. 4). In addition, most vac-
cinia-specific IFN-
 
 
 
–producing CD4
 
 
 
 cells were defined as
CD45RaNegCCR7Neg (80–91%), whereas only a few were
CD45RANegCCR7
 
 
 
 (5–10%) (Fig. 4 c). Since the prolif-
eration experiments were assessed after 3–7 d expansion, the
vaccinia-specific T cells differentiated in vitro during the
expansion process. Therefore, the original phenotype can-
not be assessed. These results suggest that most of the resid-
ual T cells capable of immediate IFN-
 
 
 
 production in re-
sponse to vaccinia decades after vaccination display the
characteristics of effector–memory T cells.
 
Effector–Memory but not Proliferative Responses Vanish 45 yr
after Antigen Priming.
 
Because murine models of lympho-
cytic choriomeningitis virus infection indicate that the qual-
ity and quantity of T cell priming during the first encounter
with antigen might determine the size of the memory T cell
pool (3), we investigated whether a higher frequency of
memory responses in vaccinees was associated with a shorter
delay from priming. We distinguished three groups accord-
ing to time since priming: 25–35, 36–45, and 
 
 
 
45 yr, with
20, 32, and 27 vaccinees per group, respectively (Fig. 5, a
and b). The proportion of IFN-
 
 
 
–producing effector–
memory T cells was highest in the 36–45 yr group (12 out
of 32 or 37.5%), and lower (5 out of 21 or 24%), but not
significantly so, among the group with the least time since
priming (25–35 yr) (Fig. 5 a). Vaccinia-specific effector–
memory responses tended to vanish in the group primed
more than 45 yr earlier (2 out of 27 or 7.5%): they did not
differ from the frequencies observed in the unvaccinated
group and were significantly lower than in the 25–35 and
36–45 yr groups (P
 
   
 
0.0068 and 0.019, respectively) (Fig.
5 a). In contrast, the proliferative vaccinia-specific memory
T cells remained stable whatever the time since priming
with 73, 73, and 70% of responders in each group (Fig. 5 b).
Thus, more than 45 yr after priming the intensity of IFN-
 
 
 
–producing effector–memory response tended to revert to
that observed in unvaccinated individuals.
To investigate whether this decay in antivaccinia im-
mune responses might simply reflect aging, we also evalu-
ated the frequencies of IFN-
 
 
 
–producing cells against con-
trol vaccine antigens, such as tuberculin, in 10 of these
vaccinees aged 25–63 yr and exposed to Bacille de Cal-
mette et Guérin
 
 
 
(BCG) in their childhood. Tuberculin-
specific IFN-
 
 
 
–producing cells were detectable in all of the
vaccinees aged 45–63 yr (range, 90–150 SFCs/million
PBMCs) and in 70% of those who were younger (age, 25–
45 yr; range, 50–343 SFCs/million PBMCs). Of note, BCG-
Figure 5. Vaccinia-specific effector–memory response vanishes 45 yr
after priming. (a and b) Distribution of vaccinia-specific responses in vac-
cinated individuals according to time since priming for ELISpot assay (a)
and proliferation assay (b). Three groups were distinguished according to
time since priming, 25–35, 36–45, and  45 yr, and were compared with
unvaccinated unexposed donors. A precise, documented vaccination
history was available for only 44 individuals as follows: one (n   12), two
(n   23), three (n   4), four (n   4), or five (n   1) immunizations. For
all graphs, statistical analysis used the  2 test. Statistical significance was set
at P   0.05 (**). ns, not significant.
Figure 6. Lack of influence of vaccinia recalls and time since last immu-
nization on the long-term persistence of IFN- –producing effector–memory
T cells. Distribution of vaccinia-specific responses in 44 vaccinated indi-
viduals with a known vaccination history, according to the number of
recalls they received up to 13 yr ago for both ELISpot (a) and proliferation
(b) assays and according to time since last immunization for ELISpot (c)
and proliferation (d) assays. The same three groups described in Fig. 3
were distinguished according to time since priming: 10–25, 25–45, and
 45 yr. For all graphs, statistical analysis was performed as in Fig. 5.Residual Memory T Cells to Smallpox Virus 1590
vaccinated individuals are still exposed to cross-reactive
mycobacteria, whereas smallpox-vaccinated individuals are
not. These data suggest that the loss of vaccinia-specific im-
mune memory does not simply reflect aging.
It is a tenet of vaccinology that booster inoculations help
to maintain high levels of long-term effector–memory im-
mune responses. Smallpox vaccination schedules typically
imposed vaccinia priming at 1 yr and recall injections at 11
and 21 yr (16, 18). Detailed information about prior vacci-
nation was available for only 44 of the 79 vaccinees. Thus,
we classified them according to the number of vaccinations
they received: one (n   12), two (n   23), three (n   4),
four (n   4), or five (n   1) immunizations. All had their
first vaccination at the age of 1 yr. We found that the num-
ber of immunizations did not affect either the rapid effec-
tor–memory response (Fig. 6 a) or the vaccinia-specific
memory T cell proliferation (Fig. 6 b).
Because the delay from priming influenced the persis-
tence of memory responses to vaccinia virus, we also
looked at the influence of the last vaccination recall injec-
tion on both types of memory responses. Figure 6, c and d,
depicts three groups according to their last antigen expo-
sure: 10–25, 25–35, and 35–50 yr ago. No correlation was
observed between the time since the last vaccinia virus ex-
posure and the detectability of memory responses assessed
by either IFN-  ELISpot or proliferation assays. Thus,
more than 25 yr after the last recall similar vaccinia-specific
long-term memory T cell responses persisted in all subjects
who received one or more immunizations, regardless of the
time since the last exposure to vaccinia virus.
Revaccination with Vaccinia Virus Boosts Previously Undetect-
able Long-Term Effector–Memory Responses. The observa-
tions above—that neither the number of immunizations nor
the delay since the last immunization influence persistence
of long-term memory—raised two questions. Could effec-
tor–memory responses, when undetectable, be reinduced in
vivo after revaccination? Would the discrepancy observed
between effector–memory and proliferative responses in
long-term vaccinees influence response after a recent anti-
gen recall? Vaccinia-specific assays were performed 1 and 2
mo. after revaccination of 17 of the 79 vaccinees tested
above. We found intense effector–memory and proliferative
vaccinia-specific responses in all but one of them (median
for positive responders, 154 SFCs/million PBMCs; range,
68–593) (Fig. 7 a). The median frequency of effector–mem-
ory T cells was twice as high in recently revaccinated indi-
viduals as in long-term vaccinees, 2 mo. after revaccination.
CD8 depletion experiments showed that both CD4 and
CD8 contributed to vaccinia-specific effector (Fig. 7 b) and
proliferative (Fig. 7 c) responses in these recently revacci-
nated individuals. Furthermore, revaccination of those sub-
jects who had no detectable IFN- –producing cells on
initial testing induced potent effector–memory and prolifer-
ative responses within 2 mo. of antigen recall (Fig. 7, a, d,
and e). This is in accordance with our finding that in vitro
proliferation of virus-specific T cells led to the expansion of
IFN- –producing cells, and it should be compared with a
recent report that vaccinia-specific responses are detectable
in all new vaccinees, 6 mo. after priming (26).
Discussion
This study investigated the remnants of T cell immunity
to vaccinia and smallpox in a population of vaccinees aged
25–68 yr who had been exposed to one or more vaccinia
challenges two decades earlier and compared it with this
Figure 7. Recent vaccinia recall allows a com-
plete immune response recovery in vaccinees
independently of the time since priming. (a) Re-
ciprocal distributions of ELISpot and proliferation
assays for 17 recently revaccinated individuals (age,
32–57 yr; median, 41) tested 2 mo after revaccina-
tion. Positive responses were defined according to
the same criteria: a stimulation index  3 and a
frequency of IFN- –producing cells  50 SFC/
million PBMCs after subtraction of background
(shown by dashed lines). (b and c) CD8-depleted
PBMCs of recently revaccinated individuals (grey
bars) compared with total PBMCs (black bars)
were tested by ELISpot (b) and proliferation (c)
assays. Graphs represent changes in IFN-  pro-
duction (d) and proliferative responses (e) of five
representative recently revaccinated individuals:
PRE (before revaccination, 1–2 mo) M1 and M2
(after revaccination).Combadiere et al. 1591
immunity in unvaccinated unexposed young volunteers.
We showed that vaccinia-specific effector–memory T cells
capable of immediate IFN-  production and memory T
cells with proliferative potential have distinct patterns of
maintenance. First, immediate effector–memory T cells
persisted (above the levels in unvaccinated unexposed naive
donors) in a much smaller percentage of long-term small-
pox vaccinees than did proliferative memory T cell re-
sponses to vaccinia; the latter were correlated to the detect-
ability of IL-2–producing cells and remained detectable in
72.5% of cases. Both memory functions were simulta-
neously observed in the 20% of the vaccinees with effec-
tor–memory responses, whereas 27.5% of the population
surveyed did not have memory T cell responses to vaccinia
any higher than the unvaccinated unexposed controls.
The discrepancy observed between immediate and pro-
liferative/IL-2–producing memory responses may be ex-
plained by various factors including the relative sensitivity of
the assays and the intrinsic properties of the cells involved.
The ex vivo ELISpot assay allows direct measurement of the
in vivo frequency of vaccinia-specific cells but has a lower
sensitivity than the proliferation assays, which include several
in vitro cycles of cell proliferation. The threshold of the
ELISpot assay was carefully established to provide 100% neg-
ative results in naive and unexposed unvaccinated donors. It
resulted in positive IFN-  responses in all but one recently
revaccinated individuals. The threshold of 50 SFCs/million
PBMCs used here is the same as that used for monitoring T
cells specific for other viruses, such as HIV, during vaccine
trials (24, 25). However, it may explain some of the discrep-
ancies between our results and a recent study that detected
extremely low frequencies of vaccinia-specific T cells pro-
ducing IFN-  and/or TNF- , as low as 10/million PBMCs
in 90% of a similar population of vaccinees—frequencies not
clearly distinguishable from the naive background (21).
However, beyond these technical distinctions proliferative
and immediate IFN-  production are two distinguishable T
cell functions: the so-called central memory T cells capable of
producing IL-2 and of proliferating and involved in clonal
expansion of vaccinia-specific T cells as opposed to the effec-
tor–memory T cells producing IFN- , which have lower
proliferative and survival abilities and are involved in antigen-
specific effector functions (27). This dichotomy has been re-
ported and discussed in humans during chronic viral infection
(27, 28). We show here for the first time the phenotypic
characteristics of long-term memory T cells persisting in hu-
mans in the complete absence of nominal antigens. The indi-
viduals who responded to vaccinia with immediate IFN- 
production maintain memory cells that belong mostly to the
CD4PosCD45RANeg11aHi27PosCCR7Neg subset. Thus,
the majority of residual vaccinia-specific CD4 T cells produc-
ing IFN-  did not express CCR7 and meet the definition of
effector–memory T cells (22), even when tested more than
25 yr after vaccination.
Both CD4 and CD8 T cells participated in the mainte-
nance of memory to smallpox in long-term vaccinees.
However, the relative contributions of each varied among
individuals independently of age or delay since priming or
boosting. In accordance with recent studies (21), we found
a predominance of CD4 memory T cells in long-term vac-
cinees. Our findings suggest that CD4 and CD8 memory T
cells may differ in their antigen dependence.
When analyzing the factors influencing persistence of
memory to smallpox/vaccinia, we found that delay from
priming had a major impact on the maintenance of im-
mune responses. More specifically, the antivaccinia pro-
liferative T cell responses were maintained over the years
after antigen exposure, but vaccinia-specific effector–
memory T cells vanished 45 yr after the first vaccinia inoc-
ulations. This loss of vaccinia-specific effector–memory T
cells does not simply reflect aging because tuberculin re-
sponses, generated by the BCG vaccine during childhood,
were maintained in the same individuals. Memory to these
two vaccines might differ because BCG-vaccinated indi-
viduals are exposed to cross-reactive mycobacteria, whereas
smallpox-vaccinated individuals are not, although some
cross-reactivity has been reported with other viruses
(molluscum contagiosum, lymphocytic choriomeningitis virus)
that might participate, to some extent, in the maintenance
of vaccinia-specific memory (15). The amount of antigen
received during the first immunization might nonetheless
determine the size of the vaccinia-specific memory pool
(7–9). Although we assumed that all vaccinated individuals
had received similar vaccinia doses, the actual number of
virus particles penetrating the skin is known to vary widely
between vaccinees, and diluting the vaccine reduces the
rate of successful vaccination (29).
In addition, we showed that the number of vaccination
recalls did not significantly influence the long-term mainte-
nance of effector–memory cells. Given that both variola
and vaccinia viruses are thought to be completely cleared
from the organism after acute infection or inoculation, vac-
cinia-specific memory appears to persist despite the absence
of both viruses for the last 25 yr. According to an emerging
consensus, murine long-term CD8 memory does not re-
quire antigen persistence (14, 30–32). Similarly, murine
CD4 T cell memory specific for the readily eliminated
Sendai virus is maintained for more than 2 yr (29, 33). The
observation that periodic reexposures to the vaccine do not
increase the size of the residual effector–memory pool
when measured decades after the last immunization sug-
gests that priming exerts a stronger influence than subse-
quent exposures on its long-term persistence. Nonetheless,
effector–memory T cells can still be reexpanded by reim-
munization in vivo, as they were on day 3 of in vitro expo-
sure; this expansion resulted in an increased frequency of
effector–memory T cells at day 7. Both vaccinia-specific
proliferative and immediate effector–memory T cell re-
sponses were detectable at high levels in all recently revac-
cinated subjects a month or two afterwards, even those for
whom effector–memory cells were undetectable before re-
vaccination and those older than 45 yr. These results show
the immune system’s capacity to mobilize effector–mem-
ory T cells rapidly in response to vaccine reexposure.Residual Memory T Cells to Smallpox Virus 1592
Preliminary reports in accordance with our findings but
on a much smaller scale offer little evidence that the effector–
memory–type component of vaccinia-specific memory de-
creases in vaccinees older than 39 (26). A recent large study
also reports the persistence of residual immunity to vaccinia
in previously vaccinated individuals (21). This immunity,
mediated by cytokine-producing effector–memory T cells,
decays with age and is not influenced by vaccine recalls (21).
The authors did not study the proliferative capacity of resid-
ual vaccinia-specific cells. Prior studies also suggest that
memory T cells for vaccinia are still expandable 20 yr after
the last immunization (20), whereas neutralizing antibody
responses decline 5 yr after vaccination (19). We found that
PMBCs of individuals who had no detectable IFN- –pro-
ducing T cells before revaccination showed an increase in ef-
fector–memory cells within 2 mo of vaccinia recall.
This large-scale study of long-term immune memory to
vaccinia in humans leads us to propose a new model of im-
mune memory to live viral vaccines: the proliferative ca-
pacity of specific memory CD4 and CD8 T cells (so-called
central memory) is maintained in the absence of antigen
and does not decay with age, at least up to 67 yr after prim-
ing; in contrast the pool of vaccine-specific effector–mem-
ory T cells decays with time in the absence of antigen but
can expand in vivo upon reexposure to the virus but only
for a limited period.
In conclusion, the end of smallpox vaccination provides
a unique model of long-term persistence of T cell memory
in humans in the absence of nominal antigen. It allows us
to distinguish two types of vaccinia-specific memory T
cells, according to their proliferative and IFN- –producing
capacities (34, 35). As suggested, proliferative central mem-
ory T cells have a greater capacity to persist in vivo and
should help mediate a stronger protective immunity (35)
than effector–memory T cells, although the question cannot
be explored in this model in the absence of circulating
smallpox. Therefore, evaluating the frequency of effector–
memory cells by immediate cytokine production capacity
might not reflect the current status of residual immune
memory to smallpox. At a time when the risks of bioterror-
rism, the recent monkeypox virus outbreaks in humans
(36), and the future intensive usage of poxviruses as vectors
for new vaccines against HIV, malaria, or tuberculosis (37)
call attention to the need for better knowledge of residual
immunity to poxviruses in the worldwide human popula-
tion, our findings offer new clues to the mechanism of per-
sistence of long-term memory to these viruses and chal-
lenge current vaccine strategies.
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